6-bromo-9-pentofuranosyl-9H-purin-2-amine | 91688-07-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 6-bromo-9-pentofuranosyl-9H-purin-2-amine
• 英文别名: 2-(2-amino-6-bromopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 91688-07-2
• 化学式: C₁₀H₁₂BrN₅O₄
• 分子量: 346.14
• InChiKey: JEAGSZXYGSYKJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
  申请人：Institut Univ. de Ciència i Tecnologia, S.A.

  公开号：EP2711007A1

  公开（公告）日：2014-03-26

  The present invention relates to the field of biotechnology. The present invention relates to 4-aminopyrazolo[3,4-d]pyrimidine, i.e. a compound of formula (I) for use in the treatment or prevention of primary and metastatic breast and prostate cancer. The present invention also relates to a combination of a compound of formula (I) with at least one further compound for use in the treatment or prevention of primary and metastatic breast and prostate cancer. The present invention further relates to a pharmaceutical composition comprising the compound of formula (I) or the combination.

  本发明涉及生物技术领域。本发明涉及 4-氨基吡唑并[3,4-d]嘧啶，即用于治疗或预防原发性和转移性乳腺癌和前列腺癌的式 (I) 化合物。本发明还涉及一种式（I）化合物与至少另一种化合物的组合物，用于治疗或预防原发性和转移性乳腺癌和前列腺癌。本发明还涉及一种包含式（I）化合物或组合物的药物组合物。